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Low blood glucose, hypoglycaemia, has been implicated as a possible contributing factor to 
sudden cardiac death (SCD) in people with diabetes but it is challenging to investigate in clinical 
studies. We hypothesised the effects of hypoglycaemia on the sinoatrial (SA) node in the heart to 
be a candidate mechanism and adapted a computational model of the human SA node action 
potential developed by Fabbri et al, to investigate the effects of hypoglycaemia on the pacemaker 
rate. Using Latin hypercube sampling, we combined the effects of low glucose on the hERG 
channel with reduced blood potassium, hypokalaemia and added sympathetic and 
parasympathetic stimulus. We showed that hypoglycaemia on its own causes a small decrease in 
heart rate but there was also a marked decrease in heart rate when combined with hypokalaemia. 
The effect of the sympathetic stimulus was diminished, causing smaller increase in heart rate, 
with low glucose and hypokalaemia compared to normoglycaemia. In contrast, the effect of the 
parasympathetic stimulus was enhanced, causing greater decrease in heart rate. We therefore 
demonstrate a potential mechanistic explanation for hypoglycaemia-induced bradycardia and 
show that sinus arrest is a plausible mechanism for SCD in people with diabetes. 
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Abbreviations: 
AP - action potential 
APA – action potential amplitude 
APD90 – action potential duration at 90% repolarisation 
bpm – beats per minute 
CL – pacemaker cycle length 
DDR - diastolic depolarisation rate 
DDR100 – early (first 100ms) diastolic depolarisation rate 
gKr – normalised conductance of the delayed rectifier potassium current (IKr) 
Gluo – extracellular glucose concentration 
IVshift – shift in the current-voltage relationship of IKr   
hERG channel – human ether-a-go-go-related gene (HERG) potassium channel 
Ko - extracellular potassium concentration 
MDP - maximum diastolic potential 
PP - peak action potential 
SAN – sinoatrial node 
SCD – sudden cardiac death 
NG – normoglycaemia 




Blood glucose levels are elevated in both type 1 and type 2 diabetes. Insulin is used to 
therapeutically lower high glucose in individuals with type 1 and long-standing type 2 diabetes, 
however, this commonly results in iatrogenic hypoglycaemia; one major barrier in achieving and 
maintaining normal glucose control in diabetes (1). Insulin causes glucose to fall, but in 
individuals with diabetes, insulin levels are reduced both due to auto-immune damage to the 
pancreatic  cells (type 1 diabetes) or a combination of impaired insulin secretion and action 
(type 2 diabetes). In both types of diabetes, exogenous insulin is used to lower glucose 
therapeutically but due to the limitations of current insulin delivery, insulin replacement is 
unphysiological. It is challenging to achieve stable basal concentrations and those with insulin 
treated diabetes are subject to both hyper-and hypoglycaemia. Attempts to mimic normal glucose 
levels through intensive insulin therapy increase the risk of severe hypoglycaemic episodes. The 
effects of hypoglycaemia on the cardiovascular system have only recently emerged and severe 
hypoglycaemia has been associated with increased mortality in randomised trials (2,3). In one of 
the trials, intensive glucose therapy resulted in a six-fold increase in severe hypoglycaemia (2). 
Over one third of deaths were attributed to sudden cardiac death (SCD), raising the possible link 
between hypoglycaemia and cardiac arrhythmias. 
Indeed, there is growing evidence in recent clinical and animal studies that hypoglycaemia might 
contribute to malignant cardiac arrhythmias leading to SCD. Severe hypoglycaemia in response 
to glucose therapy was associated with increased risk of arrhythmic death in individuals with 
type 2 diabetes (3). Spontaneous nocturnal hypoglycaemia was also implicated in the deaths of 
young people with type 1 diabetes. The term ‘dead in bed syndrome’ was introduced to describe 
these unexpected deaths (4), which were attributed to SCD. Subsequent studies reported a 
relatively large proportion of unexplained deaths in this population (5,6). Although rare in 
absolute numbers, SCD is 10-fold higher in young people with type 1 diabetes compared to those 
without diabetes (7). In observational studies, we and others reported increased risk of 
arrhythmias, including slow heart rate, bradycardia, during spontaneous hypoglycaemia versus 
normoglycaemia (8–11). These arrhythmias could be related to abnormal cardiac repolarisation 
observed in spontaneous (12) and experimental hypoglycaemia studies, where hypoglycaemia 
was induced by infusion of insulin (13–15). Experimental hypoglycaemia in rats can cause lethal 
cardiac arrhythmias, although at glucose levels significantly lower compared to those in human 
studies (16). 
Possible hypoglycaemia-induced proarrhythmic mechanisms include the direct effect of low 
extracellular glucose on the myocardial cell, which can block potassium channels that carry an 
outward current during repolarisation (17). This causes a prolongation in the cardiac action 
potential as well as lengthening of the QT interval duration in the ECG through a mechanism 
identical to that in proarrhythmic medications (18). In addition, the counterregulatory 
sympathoadrenal activation in response to hypoglycaemia causes a release of adrenaline (19), 
which in turn lowers serum potassium concentration (20) and increases intracellular calcium 
concentration (21). Combined, these can cause further QT interval prolongation and calcium 
overload and lead to proarrhythmogenic electrical instability (21). Abnormal autonomic 
responses which are common in diabetes could cause further risk in these individuals. 
The autonomic response to falling glucose levels includes sympathetic and parasympathetic 
activation, with the latter limiting the increase in heart rate during hypoglycaemia. However, 
bradycardia was also observed during spontaneous (22) and experimental hypoglycaemia (23). In 
our observational studies, we detected increased rates of bradycardia during hypoglycaemia 
compared to normoglycaemia in some individuals with diabetes (8,10,11). Bradycardia was also 
common during experimental hypoglycaemia in rats (16). These observations suggest that 
bradycardia might be an additional risk factor during hypoglycaemia, possibly by development 
of early afterdepolarisations leading to ventricular tachycardia, particularly in the presence of 
hypokalaemia (24). Our focus in this study was therefore on the effect of hypoglycaemia on the 
sinoatrial node (SAN), the heart’s natural pacemaker. 
Hypoglycaemia studies present challenges to investigators. While hypoglycaemia and cardiac 
arrhythmias are relatively common, SCD is rare, suggesting the involvement of additional 
factors, including variable and dysfunctional autonomic responses and impaired awareness of 
hypoglycaemia. Observational clinical hypoglycaemia studies are limited by an inability to 
measure electrolytes and catecholamines during spontaneous episodes of hypoglycaemia. 
Experimental studies on the other hand while more controlled, require supra-physiological 
concentrations of insulin to induce hypoglycaemia, rarely encountered in clinical practice. In 
addition, a greater fall in potassium in these studies is not representative of what happens in 
people with diabetes in the ‘free living’ condition. Animal models offer an alternative approach 
but species differences in the hormonal responses to hypoglycaemia and ensuing cardiac 
electrophysiological responses mean there are limitations in drawing conclusions from these 
data. 
In this study we have therefore used a computational model to overcome some of these 
limitations. There are currently no computational models that describe the electrophysiological 
responses to hypoglycaemia and in this study, we adapted a biophysically detailed computational 
model of a human SAN cell electrophysiology to examine the effect of hypoglycaemia on 
pacemaker rate.  
Methodology 
Model of the human sinoatrial node AP 
We used a computational model of the human SAN action potential (AP), developed by Fabbri et 
al (25). This model was in turn adapted from a computational rabbit SAN model, developed by 
Severi et al (26) by incorporating experimental data from human SAN cells. These included 
updated cell capacitance and dimension data, new formulation of the If current, new steady-state 
activation and updated conductances of delayed rectifier K+ currents (IKr and IKs) and added IKur 
current formulation. Parameters, for which human experimental data were not available, were 
fitted using automatic parameter optimisation. The modulation of the pacemaker rate in response 
to autonomic stimulation was similarly adapted from the rabbit model, where acetylcholine 
(ACh)- and isoprenaline (Iso)-induced variations were introduced to mimic the activation of the 
sympathetic (increased rate) and parasympathetic (decreased rate) nervous system, respectively. 
Further details about the model are provided in Supplementary Material. 
We ran simulations in MATLAB (The MathWorks, Inc., Natick, MA, USA) vR2017a, using 
automatically generated code for the Fabbri model obtained from the CellML platform 
(www.cellml.org). For solving numerical differentiation, we used the ‘ode15s’ function with 
relative error tolerance 10-7, absolute error tolerance 10-6 and a maximum step size of 10-3s. We 
ran the simulations for 60s and used the last beat to calculate the features of AP waveforms and 
for figures. We confirmed the stability of the main features of the AP waveform (Supplementary 
Figure 1).  
 
Features of sinoatrial AP waveform 
We characterised the sinoatrial AP waveform using a set of parameters presented by Fabbri et al 
and we calculated them based on the guidelines for standardisation of AP parameters (27). The 
following parameters were calculated: CL – cycle length of the pacemaker activity, defined as 
the duration between the peaks of two consecutive APs; PP – peak (maximum value) of the AP; 
APA – AP amplitude, defined as the difference between the maximum and minimum AP 
potentials; MDP – maximum diastolic potential preceding the PP, defined as the most negative 
repolarisation potential, DDR – diastolic depolarisation rate, DDR100 – diastolic depolarisation 
rate over the first 100ms of diastolic depolarisation, APD90 – AP duration at 90% repolarisation 
(Figure 1).  
 
Figure 1: Features of the sinoatrial AP waveform. CL – cycle length; PP – peak potential; APA – 
AP amplitude; MDP – maximum diastolic potential; DDR – diastolic depolarisation rate; DDR100 
– early diastolic depolarisation rate; APD90 – AP duration at 90% repolarisation.  
The main parameter of our interest was CL. We explored the changes induced by hypoglycaemia 
and the main features of AP responsible for these changes.  
Effect of low extracellular glucose – experimental data 
In an experimental study, Zhang et al demonstrated a direct effect of low extracellular glucose 
concentration (Gluo) on the rapid delayed rectifier potassium current (IKr) (17). Using a whole-
cell patch clamp they showed an impairment in the function of the corresponding hERG channel, 
proportional to the reduction in Gluo. Zhang et al used human embryonic kidney cells (HEK293 
cells) and in this study we assume that electrophysiological properties and responses of the 
hERG channels are similar in the heart, where hERG is highly expressed. 
Zhang et al demonstrated two separate mechanisms by which reduced Gluo alters the function of 
the hERG channel: a reduction in IKr
 current density and a shift in its current-voltage relationship. 
We digitised their graphs to numerically quantify the extent of changes. We further describe the 
effect size for both mechanisms and how we incorporated them in our model.   
 
Reduced IKr current density 
Zhang et al presented experimental data for IKr voltage-current relationships at various 
extracellular glucose concentrations: Gluo=5 (normoglycaemia), 2.5, 1, and 0mmol/L. They 
demonstrated a 10-20% reduction in current density at Gluo=2.5mmol/L compared to 5mmol/L, 
a 20-30% reduction at 1mmol/L and a 50% reduction at 0mmol/L. The current density decreased 
proportionally with decreased Gluo, but the reduction was not constant across the voltage range. 
In our model, we incorporated the drop in current density by decreasing the conductance (gKr) of 
IKr. For easier interpretation, gKr in our model represents normalised conductance, a multiplier of 
maximum conductance (4.2nS in the Fabbri model). We decreased gKr from 1 (maximum 
conductance, no effect of glucose) to 0 to investigate the overall response of the model. We then 
varied gKr within the [1, 0.7] range (100% to 70% of maximum conductance) to consider only 
physiologically relevant glucose concentrations, based on the above data. 
 
Shift in the IKr current-voltage relationship (IVshift) 
Zhang et al demonstrated that the IKr current-voltage (I-V) relationship shifted towards more 
negative potentials with reduced Gluo. Specifically, they reported a -10mV shift at Gluo = 0 vs 
5mmol/L. There was a similar -10mV shift in normalised conductance. I-V relationships were 
not shown for other Gluo, but they performed additional experiments under conditions with 
corrected osmolarity at Gluo=1mmol/L. In these experiments they measured a -3mV shift in 
normalised conductance at Gluo = 1 vs 5 mmol/L and for the purpose of our study we assumed 
that the shift in I-V curves is similar. This is since the shifts in the I-V relationship and 
conductance were similar in the experiment without correction for osmolarity. To model 
physiologically relevant effects of hypoglycaemia we varied IVshift within [-3, 0]mV range but 
we explored shifts below -3mV to test the overall response of the model. 
We extracted all relevant data by digitising the graphs and we measured the shifts at 50% I-V 
curve or conductance amplitude. In the Fabbri model, IKr is formulated as a function of 
membrane potential by combining the activation and inactivation kinetics. To model the shift in 
the I-V curve we incorporated IVshift into the membrane potential variables of all equations 
describing the activation and inactivation relationships and their corresponding time constants.   
 
Latin hypercube sampling 
We used Latin hypercube sampling for simulations where two or more input parameters were 
randomly selected from a predefined range. The sampling was performed by using the 
‘lhsdesign’ algorithm in MATLAB. The variable input parameters included gKr, IVshift and 
extracellular potassium concentration (Ko).  
 
Outline of the study 
We investigated the individual effect of each parameter gKr, IVshift and Ko on CL and features 
of the AP waveform. For each parameter, the modelling was performed for physiologically 
relevant values as well as outside this range to test the behaviour of the model and to identify 
input values that produce meaningful APs. We also looked at the combined effects of these 
parameters when their values were within physiologically relevant ranges. Using Latin 
hypercube sampling we varied gKr (gKr is a multiplier of maximum conductance) between 0.7 
and 1, IVshift between -3 and 0mV and Ko between 3.0 and 4.0mmol/L. Ko at 4.0mmol/L 
represents normal extracellular potassium concentration while Ko=3.0mmol/L indicates 
moderate hypokalaemia. Finally, we checked the combined effect of these parameters with 
additional activation of either the sympathetic or parasympathetic autonomic system. The current 
model allows only one of them to be activated at any time. 
Results 
Baseline sinoatrial AP waveform 
Fabbri et al fitted and optimised their model at Ko=5.4mmol/L, resulting in CL=0.81s 
(rate=74bpm). For the purpose of our study we changed the baseline Ko to 4.0mmol/L, closer to 
normal plasma potassium range in humans which is between 3.5 and 5mmol/L (28). This 
resulted in prolonged CL=0.92s (13.5% increase, 65 vs 74bpm), which was mostly caused by 
decreased DDR100 (40.1 vs 56.0, -28%) and lower MDP (-62.0 vs -58.9mV, -5%). The AP 
waveform at normoglycaemia (NG) and Ko=4.0mmol/L is presented in Figure 1 and its features 
at Ko=5.4 and Ko=4.0mmol/L are given in Table 1. Throughout the results section, percentage 
changes in parameters are given compared to baseline levels at Ko = 4.0mmol/L. 
 
 
 NG LG LG + low Ko 
gKr 1 1 1 0.7 1 0.7 0.7 1 0.7 
IVshift (mV) 0 0 0 0 -3 -3 0 -3 -3 
Ko (mmol/L) 5.4 4.0 3.0 4.0 4.0 4.0 3.0 3.0 3.0 
CL (s) 0.81 0.92 0.94 0.75 1.20 0.93 0.85 1.33 1.04 
PP (mV) 26.4 25.9 25.5 27.3 25.7 27.5 27.1 24.8 27.1 
APA (mV) 85.3 87.9 91.3 84.2 92.5 87.8 86.4 96.1 90.4 
MDP (mV) -58.9 -62.0 -65.8 -56.9 -66.8 -60.3 -59.3 -71.3 -63.3 
APD90 (s) 0.15 0.14 0.14 0.17 0.15 0.18 0.17 0.15 0.17 
DDR 21.6 19.0 20.6 25.1 10.9 18.3 21.9 8.4 16.2 
DDR100 56.0 40.1 35.4 51.0 34.1 52.2 44.9 35.3 33.7 
Table 1: Features of the AP waveform (rows 5 and onwards) calculated using a combination of 
input parameters (rows 2 to 4) representing normoglycaemia (NG), low glucose (LG) and a 
combination of LG and low potassium. Baseline values of input parameters (bold highlight), 
their extreme values and their combinations are considered. We changed the baseline 
Ko=5.4mmol/L in the Fabbri model to Ko=4.0mmol/L.   
 
Effect of low glucose 
Reduced conductance of the hERG channel 
We reduced gKr (gKr is a multiplier of maximum conductance) from 1 (maximum conductance) 
to 0 in steps of 0.05. The model failed to generate spontaneous AP activity at gKr<0.11. The 
relationship between gKr and CL is presented in Figure 2a. CL shortens with decreased gKr and 
the relationship is approximately linear down to gKr=0.4, followed by a plateau. The minimum 
CL at gKr=0.11 is 0.47s (-49%). The vertical blue lines indicate the [0.7, 1] range, which 
represents our estimated reduction in gKr at clinically relevant reduced glucose concentrations. 
CL at gKr=0.7 is 0.75s (-18%), APD is prolonged (+21%), the MDP potential is elevated (+8%) 
and the diastolic depolarisation rates DDR and DDR100 are increased (+32% and +27%) (Table 
1). Examples of the corresponding AP waveforms are presented in Figure 2b. 
 
Figure 2: Effect of reduced gKr on the AP waveform. a) Relationship between gKr and CL. 
Vertical lines indicate the gKr range at clinically relevant glucose concentrations. b) AP 
waveforms demonstrating shortened CL (increased rate), prolonged APD, elevated MDP and 
increased DDR with a decrease in gKr.  
 
Negative shift in IKr current-voltage relationship 
We introduced a negative shift (towards more negative potentials) in the I-V relationship 
(IVshift), starting from 0mV in steps of -0.1mV. CL exponentially increases with negative 
IVshift (Figure 3a) and the longest valid CL is obtained at -5.4mV (CL=5.94s). The blue vertical 
lines indicate the [-3, 0]mV range which represents our estimated shift at clinically relevant 
glucose concentrations. CL at IVshift=-3mV equals 1.2s (+30%) and the prolongation is mostly 
caused by decreased MDP (-8%) and depolarisation rates DDR (-43%) and DDR100 (-15%) 
(Table 1). The corresponding AP waveforms are presented in Figure 3b.  
 
Figure 3: Effect of negative IVshift on the AP waveforms. a) Relationship between CL and 
IVshift. The blue vertical lines indicate our estimated range of IVshift at clinically relevant 
glucose concentrations. b) AP waveforms showing gradual CL prolongation with IVshift, mostly 
caused by decreased MDP and DDR/DDR100. 
 
Combined effects of reduced gKr and negative IVshift 
We combined the effects of reduced gKr and negative IVshift by simultaneously sampling gKr 
from [0.7, 1] and IVshift from [-3, 0]mV ranges. We used Latin hypercube sampling to generate 
300 pairs of random and independent input variables for 300 evaluations of the model. The 
resulting CLs are presented in Figure 4. Red data indicate CL prolongation and blue data CL 
shortening versus baseline (CL=0.92s) (Figure 4a). CLs are longest at baseline gKr (gKr=1) 
combined with maximum IVshift (IVshift=-3mV) and are shortest at gKr=0.7 combined with 
baseline IVshift (0mV). The grey dashed line indicates simultaneous linear change in both 
parameters. CLs along this line are approximately constant and are slightly longer than baseline 
CL (~0.93s. +1%). In Figure 4b a projection of CL values to the gKr axis shows a gradual 
shortening of CL with decreased gKr, and for each gKr, CL is prolonged with the negative IVshift. 
The maximum and minimum CLs obtained with these parameters are 1.2s (+30%) and 0.75s (-
18%), respectively (Table 1). 
 
 
Figure 4: Combined effects of reduced gKr ([0.7, 1]) and negative IVshift ([-3, 0]mV) on CL, 
using Latin hypercube sampling (n=300). a) CL as a function of gKr and IVshift. Red data 
indicate CL prolongation and blue data CL shortening vs baseline (CL=0.92s). The grey dashed 
line indicates a linear change in both parameters. b) A projection to the gKr axis reveals gradual 
shortening of CL with reduced gKr. At each gKr, CL is prolonged with negative IVshift. The red 
dashed line shows baseline CL. 
 
1. Features of the AP waveform 
The individual effects of reduced gKr and negative IVshift produce CL changes in opposite 
directions (Figure 2) and their combined effects cancel each other out to some degree, producing 
a slight CL prolongation. A similar opposite effect is obtained with other AP features, including 
APA, MDP and DDR. For example, baseline MDP equals -62.0mV (Table 1) and the combined 
effects of gKr=0.7 and IVshift=-3mV slightly raise MDP to -60.3mV (+3%). Individual changes 
in gKr and IVshift however produce a bigger difference compared to baseline with 
minimum/maximum MDP values -66.8mV (-8%) and -56.9mV (+8%), respectively. On the 
other hand, PP, APD90 and DDR100 are predominantly affected by one of the input parameters 
but not by the other. For these AP features, the combined changes in gKr and IVshift produce 
values outside the range of their individual effects. For example, APD90 is prolonged at gKr=0.7 
(APD90=0.17s, +21%) but with added IVshift=-3mV there is a further prolongation 
(APD90=0.18s, +29%). Maximum values of PP, ADP90 and DDR100 are achieved when both gKr 
and IVshift are at the maximum of their ranges. 
 
Effect of low extracellular potassium 
With the other input parameters at baseline (normoglycaemia), we lowered Ko from 5mmol/L in 
steps of -0.1mmol/L. The relationship between Ko and CL is presented in Figure 5a in blue 
color. The lowest Ko that produces periodic pacemaker activity is 0.6mmol/L (CL=1.54s, 
+67%). CL is slightly prolonged with the decrease in Ko from 4mmol/L to 3mmol/L (blue 
vertical lines) and reaches a local maximum of 0.94s (+2%) at 3.3mmol/L. The prolongation is 
mainly caused by more negative MDP (-6%) and decreased DDR100 (-12%) (Figure 5c and Table 
1). 
   
 
Figure 5: Effect of reduced Ko on CL. a) Relationship between Ko and CL at normoglycaemia 
(gKr=1, IVshift=0mV, blue) and at low glucose (gKr=0.7, IVshift=-3mV, red). b) AP waveforms 
at normoglycaemia and low glucose (both at Ko=4mmol/L). c) Effect of reduced Ko on AP 
waveforms is small during normoglycaemia. d) Reduced Ko combined with low glucose 
produces a relatively big prolongation in CL. 
 
Combined effects of low Gluo and Ko 
We first combined the effects of low Gluo and Ko by fixing gKr and IVshift at the maximum of 
their ranges: gKr=0.7, IVshift=-3mV and by reducing Ko in a stepwise manner. Second, we 
randomly sampled all three parameters (gKr, IVshift and Ko) from their predefined ranges.  
 
Fixed gKr and IVshift, combined with stepwise reduced Ko 
With gKr and IVshift fixed at 0.7 and -3mV respectively, we decreased Ko from 5mmol/L in 
steps of -0.1mmol/L. The relationship between CL and Ko is presented in Figure 5a (red). In 
contrast to normoglycaemia (blue), the relationship is steeper for Ko between 3 and 5mmol/L 
and there is a local maximum at Ko=2.6mmol/L (CL=1.05s, +14%). At Ko =4mmol/L, CL is 
similar at normoglycaemia and low glucose (0.92s vs 0.93s, +1%) but with reduced 
Ko=3mmol/L there is a notable prolongation in CL at low glucose (CL=1.04s, +13%) vs 
normoglycaemia (CL=0.94s, +2%). The corresponding AP waveforms are presented in Figure 
5b-d. Low glucose causes APD prolongation (0.18s, +29%) with a minor effect on CL (0.93s, 
+1%) (b). Reduced potassium at normoglycaemia produces a slight prolongation in CL (c) but 
the prolongation is substantially greater when combined with low glucose (d) (CL data are given 
above).  
Randomly sampled gKr, IVshift and Ko 
We randomly varied gKr=[0.7, 1], IVshift=[-3, 0]mV and Ko=[3, 4]mmol/L using Latin 
hypercube sampling by generating 2000 independent evaluations of the model. The resulting 
CLs are presented in Figure 6. In panel a, red data designate the area of input parameters which 
cause CL prolongation and blue data the area resulting in CL shortening versus baseline. The 
grey panel indicates a linear change in gKr and IVshift. At Ko=4mmol/L, the model generates 
both prolongation and shortening of CL. With reduced Ko, the number of cases resulting in CL 
shortening is decreasing proportionally and at Ko=3mmol/L these are confined to the subspace 
gKr<0.8 and IVshift>-1mV. In panel b, absolute values of CL are presented (grey) as a function 
of Ko. There is a relatively broad spread of CL but also a systematic CL prolongation with 
reduced Ko. At Ko=3mmol/L most of the evaluations of the model result in CL prolongation vs 
baseline (red dashed line). For reference, data at normoglycaemia are shown (blue), as well as at 
low glucose with gKr and IVshift fixed at 0.7 and -3mV, respectively (red). The shortest CL is 
0.76s (-17%) at gKr=0.7, IVshift=0mV and Ko = 3.92mmol/L and the longest CL is 1.28s (+39%) 
at 1, -3mV and 3.1mmol/L, respectively. By combining the effects of randomly sampled input 
parameters, CL stays within the range obtained from parameters at the extreme ends of their 
predefined ranges (Table 1). 
 
  
Figure 6: Combined effects of low glucose and low potassium on CL using randomly sampled 
gKr ([0.7, 1]), IVshift ([-3, 0]mV) and Ko ([3, 4]mmol/L). a) Red data indicate CL prolongation 
and blue data CL shortening vs baseline (CL=0.92s). A linear change in gKr and IVshift (grey 
panel) causes CL prolongation which increases with decreased Ko. b) Range of CL values for 
random input parameters (grey). Blue data show the relationship with Ko at normoglycaemia and 
red data at low glucose (LG) when gKr and IVshift are fixed at their extremes (gKr=0.7, IVshift=-
3mV). Latin hypercube sampling, n=2000. 
 
Autonomic modulation 
We investigated the effect of autonomic modulation by separately including in the model either 
sympathetic or parasympathetic activity. In both scenarios we looked at the combined responses 
of autonomic activity, low glucose, and low potassium. To model low glucose, we first fixed gKr 
and IVshift at the extreme ends of their ranges. Second, we explored all possible outcomes by 
randomly sampling all input parameters (gKr, IVshift and Ko). 
Fixed gKr and IVshift 
At NG and Ko=4mmol/L, an addition of sympathetic activity shortens the CL from 0.92s to 
0.69s (-25%). In Figure 7a, the grey dashed line shows the AP at NG without and the blue line 
with added sympathetic activity. Low glucose (gKr=0.7 and IVshift=-3mV) combined with 
sympathetic activity further shortens the CL (0.64s, -30%, red line). An additional reduction in 
Ko causes CL prolongation, reaching 0.70s (-24%) at Ko=3.5mmol/L (yellow) and 0.78s (-15%) 
at Ko=3mmol/L (purple).  
An addition of parasympathetic activity at NG causes CL prolongation from 0.92s (Figure 7b, 
grey dashed line) to 1.27s (+38%) (blue). Low glucose combined with parasympathetic activity 
further prolongs the CL (1.36s, +48%, red). An additional reduction in Ko causes a further 
relatively big prolongation: CL=1.52s (+65%) at Ko=3.5mmol/L (yellow) and CL=1.73s (+88%) 
at Ko=3mmol/L (purple). The features of the AP waveforms are given in Table 2 and the 
relationship between CL and Ko at NG and LG is presented in Figure 8 using blue and red 
colors, respectively. 
In the simulations including sympathetic and parasympathetic activity, a reduction in Ko 
combined with LG causes CL prolongation, predominantly caused by decreased rates of diastolic 
depolarisation (DDR and DDR100) (Table 2). When combined with sympathetic activity, DDR 
and DDR100 are decreased by -23% (18.5 vs 23.9) and -22% (59 vs 67) at LG and Ko=3mmol/L 
vs LG and Ko=4mmol/L. The reductions are greater, -33%, (6.2 vs 9.3) and -38%, (25.1 vs 40.5) 
when combined with parasympathetic activity. 
 
Figure 7: AP waveforms at NG and low glucose (LG: gKr=0.7 and IVshift=-3mV) in 
combination with reduced Ko and activation of either a) sympathetic activity (Symp.Act) or b) 











gKr 1 1 0.7 0.7 1 0.7 0.7 
IVshift (mV) 0 0 -3 -3 0 -3 -3 
Ko (mmol/L) 4.0 4.0 4.0 3.0 4.0 4.0 3.0 
CL (s) 0.92 0.69 0.64 0.78 1.27 1.36 1.73 
PP (mV) 25.9 26.8 27.6 27.8 22.8 24.1 23.3 
APA (mV) 87.9 86.6 85.7 88.3 84.6 84.5 86.9 
MDP (mV) -62.0 -59.8 -58.7 -60.5 -61.7 -60.4 -63.6 
APD90 (s) 0.14 0.14 0.17 0.17 0.14 0.17 0.16 
DDR 19.0 21.9 23.9 18.5 10.4 9.26 6.22 
DDR100 40.1 58.3 67.0 59.0 34.0 40.5 25.1 
 
Table 2: Features of AP waveforms at normoglycaemia (NG), low glucose (LG), and LG 
combined with low Ko (LG+Low Ko) with added either sympathetic or parasympathetic activity. 
Baseline values of input parameters (gKr, IVshift and Ko) and AP waveform features are 
highlighted in bold. 
 
Randomly sampled gKr, IVshift and Ko 
We used the existing 2000 random sets of input parameters gKr, IVshift and Ko, presented in 
Figure 6 and evaluated the model by adding either sympathetic or parasympathetic activity. The 
range of CL values, obtained after adding sympathetic activity is shown in Figure 8a (grey). For 
reference, the grey and red dashed lines indicate baseline CL at NG without (CL=0.92s) and with 
added sympathetic activity (CL=0.69s, -25%), respectively. The model produces valid periodic 
pacemaker activity with all sets of input parameters. The relationship between CL and Ko at 
normoglycaemia is further highlighted in blue and at low glucose (gKr=0.7, IVshift=-3mV) in 
red. The AP waveforms at Ko=3, 3.5 and 4mmol/L are presented in Figure 7a. There is a trend of 
CL prolongation with reduced Ko overall, as well as at NG and LG. For the whole range of Ko, 
CL is shorter at LG compared to NG (red data are below blue) and the difference is greatest at 
Ko=4mmol/L (CL=0.64s vs 0.69s, -7%).  
The relationship between CL and Ko when combined with parasympathetic activity is shown in 
Figure 8b (grey). The grey and red dashed lines indicate baseline CL at NG without (CL=0.92s) 
and with added parasympathetic activity (CL=1.27s, +38%), respectively. There is a systematic 
CL prolongation with reduction in Ko. Some of the CLs are greater than 4s, especially at lower 
Ko, reaching CL~25s (data not shown). We show the distribution of the full extent of CL values 
on a logarithmic scale in Figure 8c. The relationship between CL and Ko at normoglycaemia is 
further highlighted in blue and at LG (gKr=0.7, IVshift=-3mV) in red. The AP waveforms at 
Ko=3, 3.5 and 4mmol/L are presented in Figure 7b. CL is prolonged with reduced Ko, but the 
prolongation is greater at LG vs NG (red data above blue), with the biggest difference at 
Ko=3mmol/L (CL=1.73s vs 1.50, +15%).  
Some combinations of input parameters with added parasympathetic activity do not produce 
periodic pacemaker activity (data not presented, see below).  
 
  
Figure 8: CL with randomly sampled gKr [0.7, 1], IVshift [-3, 0]mV and Ko [3, 4]mmol/L, using 
Latin hypercube sampling (N=2000) with the addition of either a) sympathetic activity or b,c) 
parasympathetic activity. Blue and red data present the relationship between CL and Ko at NG 
and at LG (gKr=0.7, IVshift=-3mV), respectively. Outlier CL values are not shown in panel b. 
The distribution of the full range is presented on logarithmic axis in panel c. Some combinations 
of input parameters combined with parasympathetic activity did not produce valid pacemaker 
activity (data not shown). The grey dashed lines show baseline CL at NG (CL=0.92s). The red 
dashed lines show CL at NG combined with (a) sympathetic activity (CL=0.69s) and (b) 
parasympathetic activity (CL=1.27s).  
To identify input parameters which in combination with parasympathetic activity produce long 
CL or no pacemaker activity, we divided the parameter space as shown in Figure 9a. Red data 
indicate CL prolongation and blue data CL shortening compared to NG with added 
parasympathetic activity (CL=1.27s). Green data indicate CL>2s and purple data indicate invalid 
CL with no periodic pacemaker activity. At Ko=4mmol/L, all simulations result in valid periodic 
activity, with some CLs longer than 2s (see also Figure 8b). These are roughly confined to the 
area with gKr>0.9 and IVshift<-2mV. At Ko=3mmol/L, this area extends to gKr>0.8 and IVshift<-
1mV (green circles). At Ko=3.7mmol/L, the model stops producing pacemaker activity around 
gKr=1 and IVshift=-3mV. At Ko=3mmol/L, this area extends to gKr>0.88 and IVshift<-1.8mV. 
Figure 9b shows examples of APs over 40s simulations. Baseline AP (CL=0.92s) is shown in the 
top row, followed by CL=2s in the second row and sinoatrial pauses in rows 3 to 5. The 
penultimate row shows the longest CL (around 25s), and the last row shows an example with no 
periodic pacemaker activity. 
 
 
Figure 9: a) Classification of CL values produced with randomly sampled gKr [0.7, 1], IVshift [-
3, 0]mV and Ko [3, 4]mmol/L when combined with parasympathetic activity. Red data indicate 
CL prolongation and blue data CL shortening versus baseline + parasympathetic activity 
(CL=1.27s). Green data indicate CL>2s and purple data invalid CL where the model did not 
produce periodic AP. b) Examples of simulated APs: baseline (CL=0.92s, top row), CL=2s 
(second row), sinoatrial pauses (rows 3-6) and no periodic AP (last row). Latin hypercube 





In this first study investigating the effects of hypoglycaemia on the SA node electrophysiology 
we demonstrate the following findings. First, in response to hypoglycaemia, the reduced 
conductance of the hERG channel and the shift in its current-voltage relationship produce 
opposite effects on the pacemaker rate. When combined, they cancel each other out, resulting in 
a small decrease in heart rate. Second, mild hypokalaemia causes a slight decrease in heart rate. 
When combined with hypoglycaemia, there is a marked further decrease in heart rate. Third, 
hypoglycaemia combined with sympathetic activity enhances the effect of sympathetic activity 
by further increasing the heart rate compared to normoglycaemia. However, when 
hypoglycaemia is combined with hypokalaemia and sympathetic activity, the effect of 
sympathetic activity is diminished, causing a smaller increase in heart rate compared to that at 
normoglycaemia with added sympathetic activity. Fourth, hypoglycaemia enhances the effect of 
parasympathetic activity by causing a greater decrease in heart rate compared to 
normoglycaemia. Hypoglycaemia combined with hypokalaemia and parasympathetic activity 
causes a further marked reduction in heart rate, resulting in sinoatrial pauses, sinus arrest and 
block of pacemaker activity.  
Combined, the above findings indicate that hypoglycaemia tends to decrease the pacemaker rate 
of the SA node. During experimental hypoglycaemia, where glucose was reduced in a controlled 
environment using insulin infusion, hypoglycaemia counterregulation caused a significant 
increase in circulating adrenaline and noradrenaline concentrations together with a significant 
decrease in potassium in healthy people (15) and in people with type 2 (15) and type 1 diabetes 
(14). Despite the significant increase in adrenaline and noradrenaline, there was a relatively 
small (about 3 bpm) increase in heart rate during hypoglycaemia compared to normoglycaemia 
(14,15). It is therefore possible, that decreased glucose and potassium levels counteract the 
effects of the autonomic nervous system at the level of the SA node. Robinson et al have 
reported the results of experimental studies in healthy subjects where they restored normal 
concentrations of potassium during both normoglycaemia and hypoglycaemia (14). They have 
shown that heart rate did not change during normoglycaemia after potassium has been added 
(Ko=3.6 vs 4mmol/L). On the other hand, there was an approximate 7 bpm increase in heart rate 
(61 vs 68bpm, +11%) when potassium was added (Ko=3.2 vs 3.9mmol/L) during 
hypoglycaemia. These data are in line with our findings that decreased potassium does not 
significantly affect the heart rate during normoglycaemia but causes a decrease in heart rate 
when combined with decreased glucose. For comparable values of Ko, our model shows a 2% 
higher heart rate during normoglycaemia and a 9% higher heart rate during hypoglycaemia. 
In our study we demonstrate a potential mechanistic explanation for hypoglycaemia-induced 
bradycardia, which has been observed during clinical episodes in people with type 1 (29) and 
type 2 diabetes (22). We have undertaken several observational studies, where we compared 
rates of cardiac arrhythmia during spontaneous hypoglycaemia vs normoglycaemia. We 
observed increased incidences of bradycardia in people with type 1 diabetes (10), with type 2 
diabetes (8) and with type 2 diabetes after discharge from ICU (11). However, increased rates of 
bradycardia were only detected in a few individuals. We speculated that these effects are 
idiosyncratic and that mechanisms, other than those involved in hypoglycaemia 
counterregulation might contribute to the development of bradycardia (10,11,30). These could 
include autonomic dysfunction and/or abnormal and variable autonomic responses such as those 
observed during experimental hypoglycaemia, where early parasympathetic withdrawal was 
followed by parasympathetic reactivation during sustained hypoglycaemia (15). Nocturnal 
hypoglycaemia could also increase the risk as sleep and prone position diminish the 
sympathoadrenal responses during the night (31). Our findings that decreased blood glucose and 
potassium diminish the effect of the sympathetic activity and enhance the parasympathetic 
activity might further exacerbate the risk of bradycardia in the above cases. 
To validate the responses of our model during hypoglycaemia, we used the heart rate differences 
between matched spontaneous hypoglycaemia and normoglycaemia episodes from our 
observational study in people with type 1 diabetes (10). We chose only nocturnal episodes due to 
diminished sympathoadrenal responses which in turn also cause a smaller reduction in Ko. Our 
computational model shows an approximate -1% decrease in heart rate during hypoglycaemia at 
Ko=4mmol/L. In our observational study there was a nonsignificant +2% increase in heart rate 
during hypoglycaemia vs normoglycaemia with a mean difference 1.5bpm (95%CI -1.3, 
4.4)bpm. In a similar study, Koivikko et al (32) reported a +2% increase. Our computational data 
are within the confidence intervals of those from the above observational studies and the 
difference in trends could be partly due to counterregulatory sympathetic activation.  
There are several conditions which could combine with the effects of hypoglycaemia to further 
promote decreased pacemaker rate at the SA node. Channelopathies, such as mutations in the 
HCN4, SCN5A and KCNQ1 genes, which encode ion currents If, INa and IKs, can lead to reduced 
pacemaker rate. In addition, remodeling of the If depolarisation current in trained athletes, which 
causes decreased resting heart rate and potential training-induced bradycardia (33) could lead to 
increased risk during hypoglycaemia. These cases could be further explored in the computational 
model of the human SA node as well as in observational or experimental hypoglycaemia studies. 
In our model, we show a gradual increase in pacemaker rate with decreased gKr (Figure 2). This 
contradicts experimental data from animals, where selective blockage of IKr resulted in decreased 
rates in rabbit (34) and guinea pig (35) SA nodes. Due to lack of human experimental data to 
confirm our findings, we explored the reduction of gKr in a computational model of the rabbit SA 
node. We chose the Severi model (26), which is the parent model of the one used in this study. 
The AP waveforms and the relationship between gKr and CL are presented in Figure 10. CL is 
proportionally prolonged with reduced gKr (Figure 10a) and the pacemaker activity is abolished 
with complete block of IKr (gKr=0, Figure 10b). CL prolongation is accompanied by APD 
prolongation, elevation of MDP and decreased DDR. This is in line with experimental data from 
the rabbit SA node (34).  
 
Figure 10: Effect of reduced gKr on CL in a computational model of rabbit SA node. a) CL is 
prolonged with the reduction in gKr. b) The corresponding AP waveforms indicate APD 
prolongation, elevated MDP and reduced DDR. The model doesn’t generate AP with gKr=0. 
In our human model, a reduction in gKr is accompanied by APD prolongation and elevation of 
MDP, as in the rabbit model. In contrast to the rabbit model, DDR increases in the human model 
(Table 1). One of the reasons for differences between the models is the roughly 2.5 times higher 
resting pacemaker rate in rabbits (CL=0.92s in human vs 0.36s in rabbit). While APD 
prolongation is similar in both models, this makes up a much bigger proportion of CL in the 
rabbit AP. In Figure 10b, APD prolongations are similar to the prolongations of CL while the 
opposite effects of elevated MDP and decreased DDR on CL seem to cancel each other out. In 
contrast, the duration of diastolic depolarisation is much longer in the human model, making the 
CL more susceptible to changes in DDR.  
To further investigate the differences between DDR responses in both models, we compared the 
major currents responsible for diastolic depolarisation at gKr=1 vs gKr=0.5. In the rabbit model, 
the amplitude of If current is relatively high vs the other currents and its amplitude decreases by 
about 50% with reduced gKr (Supplementary Figure 2). Similarly, the amplitude of INaCa 
markedly decreases. In contrast, the amplitude of the If current is much smaller in absolute terms 
as well as relative to the other currents in the human model (Supplementary Figure 3). In 
addition, the amplitude of INaCa slightly increases with reduced gKr. These differential responses 
in currents, combined with the higher resting rate in rabbits could explain the differences 
between the gKr /CL relationship in humans vs rabbits. It is also possible that the decreased 
pacemaker rate in response to reduced gKr in rabbits contributes to the reduction of heart rate and 
occurrence of bradycardia during experimental hypoglycaemia in rabbits (16). 
The key strength of our study is that we explored for the first time the electrophysiological 
effects of hypoglycaemia on the SA node. Furthermore, to mimic the physiological conditions in 
humans, we added the stimuli of hypokalaemia as well as sympathetic and parasympathetic 
stimulation. This approach overcomes some of the technical, biological and ethical constraints of 
in-vivo human and animal studies. One of the limitations of the study is the lack of detailed 
experimental data on the effect of extracellular glucose concentration on cardiac cell 
electrophysiology. Zhang et al demonstrated the main effects of low glucose on the hERG 
channel (17), but experimental data at finer glucose increments would greatly improve the 
understanding of the balance between increased heart rate, caused by reduced conductance of the 
channel versus slowing of the rate caused by the shift in its current-voltage properties and how 
these relate to clinically relevant glucose levels. To the best of our knowledge, there is no 
evidence of any other cardiac ion channel being affected by hypoglycaemia.  
Fabbri et al optimised their model to reproduce baseline electrophysiological characteristics from 
limited number of human experimental data and validated it against baseline heart rates observed 
in common ion channel mutations. Given the lack of experimental data, the model is not 
optimised and validated for variations in heart rate and altered extracellular ion concentrations. 
Loewe et al extended the Fabbri model to work at variable Ko concentrations by including a new 
formulation of IKr, where gKr is dependent on Ko (36). Their model showed a positive 
relationship between heart rate and Ko and they found that this was in disagreement with data 
from the general population, which showed a negative linear relationship. Our model, as the 
extended Fabbri model, shows a positive relationship between heart rate and Ko. This could 
mean that our model overestimates the CL at Ko=3mmol/L during normoglycaemia as well as 
with low glucose and in combination with parasympathetic activity. This behaviour of our model 
could be inherited from the parent model. Indeed, existing human atrial models show divergent 
and sometimes unphysiological responses to changing extracellular Ko (37) and the 
corresponding electrophysiological conditions remain to be explored. Finally, the Fabbri model 
offers selective activation of either sympathetic or parasympathetic activity. In reality, both 
branches of the autonomic system are continuously active and they complement each other to 
modulate the pacemaker rate. The responses of their combined activities and how these relate to 
their individual effects, observed in this study, remain to be investigated. 
Conclusions 
Computational modelling has the potential to clarify electro-pathophysiological effects of 
hypoglycaemia. We have shown that sinus arrest, a case of extreme bradycardia, is a plausible 
mechanism for SCD, possibly more probable than tachycardia during the night. Investigation of 
confounding factors that lead to development of abnormal cardiac responses, as well as 
modelling of different cardiac cells at different levels may help to identify individuals with 
diabetes who are at increased risk of sudden death due to sinus arrest during hypoglycaemia. 
This has important clinical implications because equivalent studies are not feasible or are 
challenging to perform in a clinical setting. 
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